NGN. Yu. Gorokhova

N. Yu. Gorokhova

*This is an algorithmically generated author record based on publicly available information.

N. Yu. Gorokhova has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of medical and social research and assessment of quality of life in myasthenia gravis

    by Ya. V. Vlasov, Yu. A. Merkulov, V. M. Alifirova, M. V. Ambroskina, K. Z. Bakhtiyarova, S. B. Blinova, Z. A. Goncharova, N. Yu. Gorokhova, I. V. Greshnova, L. G. Zaslavsky, et al.

    Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.


  • Open Access

    Clinical and social study and assessment of quality of life in patients with neuromyelitis optica spectrum disorders

    by Yu. V. Vlasov, V. M. Alifirova, N. N. Babicheva, K. Z. Bakhtiyarova, O. V. Bragina, Z. A. Goncharova, N. Yu. Gorokhova, I. V. Greshnova, O. V. Dzundza, E. A. Dubchenko, et al.

    Neuromyelitis optica spectrum disorders (NMOSD, formerly known as opticoneuromyelitis or Devic's disease) are severe chronic autoimmune inflammatory diseases of the central nervous system (CNS) associated with high disability in the absence of adequate treatment. In Russia, no assessment of the medical and social characteristics of this disease and the quality of life of patients has been conducted, which complicates the assessment of the prognosis and the development of medical and social management strategies for these patients.Objective: to analyse the medical and social characteristics and quality of life of patients diagnosed with NMOSD (opticoneuromyelitis).Material and methods. The condition of patients with a confirmed diagnosis of NMOSD or opticoneuromyelitis was assessed using a specially designed questionnaire, which also included questions about patients' attitudes towards their health. The SF-36 international quality of life questionnaire was used to score quality of life. Based on the results of the study, 280 patients diagnosed with NMOSD were surveyed in 21 regions of the Russian Federation.Results. Most patients with NMOSD who are observed by neurologists receive specialised treatment, but half of all patients with NMOSD currently experience some difficulties in obtaining drug therapy. Over the past year, 28.6% of respondents reported an improvement in their health, 39.6% reported no change, and 31.8% reported a deterioration. Self-assessment of health status declines sharply in patients over 55 years of age. The majority (74%) of patients report a decline in vision. Every second patient noted a decrease in vision at the onset of the disease. Severe movement disorders are characteristic, and for the majority (91%) of patients with NMOSD, strenuous physical activities such as running and weight training are not possible. Patients with disability groups I or II are more limited in their physical and mental resources. Patients receiving treatment significantly better assess changes in their health over the past year, both physical and psychological. Those who receive specialized drug therapy have a much better perception of their own health and its prospects. The SF-36 quality of life indices for NMOSD are significantly lower than normal, primarily in terms of physical condition, but also in terms of psychological well-being.Conclusion. In NMOSD, there are pronounced changes in the quality of life of patients, both according to the original questionnaire and according to the SF-36 scale. Receiving timely and adequate treatment significantly improves these indicators and the prognosis.